News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
News FDA rejects Mylan and Biocon biosimilar, citing manufacturin... Neulasta biosimilar hits trouble with regulators because of manufacturing issues
News Leukaemia patients to get access to AbbVie's Venclyxto via C... Cancer Drugs Fund will reimburse medicine on interim basis
News Janssen's Imbruvica runs into trouble with NICE in mantle ce... NICE suggests interim CDF funding while further data is gathered.
News Novartis joins with Berkeley to tackle "undruggable" targets Project will focus on areas such as cancer and infectious diseases
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
